AL8326
Acute Myeloid Leukemia
Phase IIActive
Key Facts
About Shanghai Allist Pharmaceuticals
Shanghai Allist Pharmaceuticals, founded in 2004, is a publicly traded biopharmaceutical innovator with a mission to leverage technology for improving patient lives. The company has successfully transitioned from a research organization to an integrated enterprise with a focus on kinase inhibitors for oncology and drugs for metabolic diseases, culminating in a high-profile IPO on the Shanghai STAR Market. Its strategy centers on advancing a deep clinical pipeline, capitalizing on China's supportive innovation policies, and pursuing global partnerships to maximize the value of its novel therapeutics.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| AFM28 | Affimed | Phase 1/2 |
| AML (N-Act) AI | Biostate AI | Development |
| Navtemadlin (KRT-232) | Kartos Therapeutics | Phase 1/Phase 2 |
| QL325 | QLSF Biotherapeutics | Phase 1 |
| NPM1 Testing in AML | Diatech Pharmacogenetics | Commercial |
| Joint Development for AML | Ordaos Bio | Pre-clinical |
| RG6356 (RO7434656) | Chugai Pharmaceutical | Phase III |